Mometasone Nasal Spray |
Nasonex |
Article: Mometasone furoate
| Image:Mometasone furoate.png | |
| Mometasone furoate | |
| Systematic (IUPAC) name | |
| 9-chloro-17-(2-chloroacetyl)-11,17-dihydroxy-10,13,16-trimethyl-6,7,8,11,12,14,15, 16-octahydrocyclopenta[a]phenanthren-3-one | |
| Identifiers | |
| CAS number | 105102-22-5 83919-23-7 as Furoate |
| ATC code | D07AC13 D07XC03, R01AD09, R03BA07 |
| PubChem | 123620 |
| DrugBank | APRD00289 |
| Chemical data | |
| Formula | C22H28Cl2O4 for Mometasone C27H30O6Cl2 as Furoate |
| Mol. weight | 427.361 g/mol |
| Pharmacokinetic data | |
| Bioavailability | Nasal spray is virtually undetectable in plasma |
| Protein binding | 98% to 99% |
| Metabolism | hepatic |
| Half life | 5.8 hours |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. | ? |
| Legal status | |
| Routes | topical, nasal |
Mometasone furoate (also referred to as Mometasone) is a moderately potent glucocorticoid steroid used in the treatment of inflammatory skin disorders (such as eczema and psoriasis) and allergic rhinitis (such as hayfever) unresponsive to less potent corticosteroids. It is marketed by Schering-Plough under the brand names Elocon® as a cream or ointment and as Nasonex® nasal spray.
Categories: Glucocorticoids | Pharmacology stubs

Not Signed In -


